Crohn Disease clinical trials
The registry lists 1,992 studies for Crohn Disease across more than 10 countries. 477 are recruiting or about to start. 1,399 of them are mainly about Crohn Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
ClinicalTrials.gov finds 2,118 studies for Crohn Disease. How that becomes 1,990 here
This page counts the studies the registry files under Crohn Disease, and those it files under no condition that list Crohn Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 2,118Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −19List Crohn Disease as a condition, but the registry did not file them under itMost often written as “Pediatric Crohn's Disease” (5), “Pediatric Crohns Disease” (4), and “Perianal Crohn Disease” (2). The registry filed them under other conditions only, most often Pediatric Crohn's disease (5) and Inflammatory Bowel Diseases (4).
- −109Match it another way74 name it in the title, 3 in a keyword, and 32 by a synonym or other text the search reads.
- 1,990The count on this page41 of them list Crohn Disease in their own words; the registry filed them under no condition.
Get an email when these change. Save the Crohn Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Takeda (69) · AbbVie (46) · Sixth Affiliated Hospital, Sun Yat-sen University (34) · Janssen Research & Development, LLC (25) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (22) · Mayo Clinic (21) · Assistance Publique - Hôpitaux de Paris (19) · Jinling Hospital, China (17)
What is being tested here
Drugs under test in Crohn Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Infliximab | 10 | 12 | 41 |
| Vedolizumab | 10 | 16 | 39 |
| Risankizumab | 7 | 8 | 16 |
| Mirikizumab | 7 | 4 | 10 |
| Guselkumab | 6 | 8 | 12 |
| Adalimumab | 3 | 24 | 41 |
| Ustekinumab | 3 | 9 | 21 |
| Duvakitug | 3 | 2 | 5 |
| Zasocitinib | 3 | 0 | 3 |
| Upadacitinib | 2 | 4 | 8 |
Drug classes tested here Antimetabolites 5 open · JAK inhibitors 5 open · Tyrosine kinase inhibitors (TKIs) 5 open · Corticosteroids 4 open · Alkylating agents 4 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. · Phase 3 · Assistance Publique - Hôpitaux de Paris
- Dec 2026Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease · Phase 3 · Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
- Mar 2027A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. · Phase 3 · AbbVie
- Mar 2027A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease · Phase 3 · Janssen-Cilag Ltd.
- Mar 2027Precise Infliximab Exposure and Pharmacodynamic Control · Phase 3 · Children's Hospital Medical Center, Cincinnati
- May 2027Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal · Phase 3 · Assistance Publique - Hôpitaux de Paris
- Jun 2027Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients · Phase 3 · Janssen-Cilag Ltd.
- Jun 2027A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease · Phase 3 · Takeda
- Sep 2027A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 · Phase 3 · AbbVie
- Sep 2027A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) · Phase 3 · Takeda
Who these studies take
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger. 95 (27%) take children under 18. 9 (3%) are for women only and 3 (1%) for men only; 56 (16%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 61 (17%) | 59 (17%) |
| 18 | 328 (93%) | 322 (91%) |
| 30 | 312 (88%) | 306 (87%) |
| 40 | 311 (88%) | 306 (87%) |
| 50 | 308 (87%) | 302 (86%) |
| 65 | 295 (84%) | 291 (82%) |
| 75 | 249 (71%) | 244 (69%) |
| 85 | 173 (49%) | 168 (48%) |
Across all 1,992 studies, recruiting or not: 43% stop at 75 or younger and 24% at 65; 24% take children; 2% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Crohn Disease studies take
Of 88 phase 3 interventional studies under Crohn Disease, half reached primary completion within 49 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 22 mo10–41 · 61 studies | 16 mo5–28 · 33 studies | — |
| Phase 2 | 34 mo23–51 · 83 studies | 33 mo20–45 · 56 studies | — |
| Phase 3 | 49 mo36–69 · 88 studies | 46 mo35–69 · 70 studies | — |
| Phase 4 | 56 mo35–68 · 70 studies | — | 56 mo44–71 · 54 studies |
| Interventional, no phase | 45 mo21–65 · 300 studies | — | 46 mo22–67 · 288 studies |
| Observational | 41 mo29–88 · 304 studies | 36 mo28–60 · 73 studies | 47 mo32–101 · 231 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting6
- Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter StudyNov 6, 2026NCT07719426
- A Study of SL-325 in Crohn's Disease PatientsNov 3, 2026NCT07753850
- Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseOct 28, 2026NCT07799428
- Risankizumab for Refractory Perianal Fistulizing Crohn's DiseaseOct 23, 2026NCT07872449
- Virtual hIStology of Crohn's Disease Ex-vivo Resected Anatomical LesionsOct 21, 2026NCT07413653
Show 1 moreShow fewer
Stopped3
- A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)TerminatedOct 22, 2026NCT07222189
- The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )TerminatedOct 21, 2026NCT03999580
- A Study on Infections in Adults With Ulcerative Colitis/Crohn's DiseaseWithdrawnOct 15, 2026NCT07250815
Newly registered11
- Phase 2 Study of pH Gastrilex™ (Enteric-Coated Amorphous Calcium Carbonate Capsules) in Moderate-to-Severe Crohn's DiseaseNov 10, 2026NCT07928700
- Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's DiseaseNov 9, 2026NCT07925450
- An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesNov 6, 2026NCT07923383
- Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO StudyNov 4, 2026NCT07916727
- Study of Single and Multiple Ascending Doses of CM551 in Healthy ParticipantsOct 28, 2026NCT07900945
Show 6 moreShow fewer
- Mechanical Bowel Preparation Prior To Sphincter-Sparing Surgery For Complex Anal FistulaeOct 27, 2026NCT07897539
- MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)Oct 23, 2026NCT07892651
- Validation and Clinical Impact of GLIM Criteria in Patients With Inflammatory Bowel DiseaseOct 22, 2026NCT07888023
- Microencapsulated Sodium Propionate in IBD Microbiota ModulationOct 20, 2026NCT07883044
- Impact of Ultra-Processed Food Reduction on Remission Duration in Pediatric Crohn's DiseaseOct 20, 2026NCT07884045
- Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel DiseaseOct 16, 2026NCT07877649
Studies
Recruiting first, then most recently updated. Showing 50 of 1,992. Browse all 1,992 → or search them.
- PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel DiseaseRecruitingNCT06758024Not applicable1 country
- Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's DiseaseEnrolling by invitationNCT07356232Not applicable1 country
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 12 countries
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruitingNCT047513961 country
- A Study of SL-325 in Crohn's Disease PatientsRecruitingNCT07753850Phase 21 country
- A Survey of Darvadstrocel in People With Crohn's DiseaseRecruitingNCT051130951 country
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)RecruitingNCT06651281Phase 37 countries
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)RecruitingNCT06430801Phase 347 countries
- Longitudinal Immunophenotyping of Patients With Inflammatory Bowel DiseaseRecruitingNCT076195471 country
- Iron Treatment for Iron Deficiency Anemia in Children and Young Adults With Crohn's DiseaseRecruitingNCT07925450Phase 41 country
- Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter StudyRecruitingNCT077194261 country
- An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesNot yet recruitingNCT07923383Phase 1
- Ibd CAncer and seRious Infections in France (I-CARE 2)RecruitingNCT060895901 country
- MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel DiseaseEnrolling by invitationNCT06788340Phase 41 country
- Oral N-acetylglucosamine in Crohn's DiseaseNot yet recruitingNCT07225998Phase 21 country
- A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07298421Phase 38 countries
- The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.RecruitingNCT060060392 countries
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingNCT06937099Phase 322 countries
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06226883Phase 228 countries
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseRecruitingNCT07483073Phase 210 countries
- Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's DiseaseRecruitingNCT07292012Phase 41 country
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseRecruitingNCT07483099Phase 210 countries
- Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO StudyRecruitingNCT07916727Not applicable1 country
- A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07577843Phase 330 countries
- A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative ColitisNot yet recruitingNCT078487371 country
- A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNot yet recruitingNCT07746765
- A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in GermanyRecruitingNCT071023681 country
- A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's DiseaseRecruitingNCT07363044Not applicable6 countries
- A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)RecruitingNCT072422481 country
- A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative ColitisRecruitingNCT076063391 country
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07196722Phase 2/328 countries
- A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)RecruitingNCT07310095Phase 41 country
- A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative ColitisRecruitingNCT043721081 country
- A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07499232Phase 317 countries
- A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 41 country
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 318 countries
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05923073Phase 317 countries
- An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With UstekinumabRecruitingNCT03167437Phase 1/21 country
- A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingNCT05837897Phase 31 country
- A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseRecruitingNCT06958536Phase 212 countries
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06233461Phase 225 countries
- NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's DiseaseRecruitingNCT07683325Phase 23 countries
- INSIGHT-IBD Pragmatic StudyEnrolling by invitationNCT07686757Phase 41 country
- Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseRecruitingNCT07799428Not applicable1 country
- Study of Single and Multiple Ascending Doses of CM551 in Healthy ParticipantsNot yet recruitingNCT07900945Phase 11 country
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingRecruitingNCT06581328Phase 41 country
- Mechanical Bowel Preparation Prior To Sphincter-Sparing Surgery For Complex Anal FistulaeNot yet recruitingNCT07897539Not applicable1 country
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingNCT07697456Phase 25 countries
- Robotic Inflammatory Bowel Disease Development, Learning and Efficacy StudyRecruitingNCT065794431 country
- PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's DiseaseRecruitingNCT05928039Phase 41 country